Replimune raises $100M in PIPE to fund RP1 commercialization; BLA filing on track for 2H 2024

Replimune Group, Inc.

Issued 5.67M shares at $8.82/share and 5.67M pre-funded warrants at $8.819/warrant.
Gross proceeds ~$100M; expected closing June 14, 2024.
Proceeds to fully scale up for RP1 commercial launch in skin cancers, potential path to profitability.
Led by life-sciences institutional investor; Redmile, RTW, Boxer Capital participated.
RP1 IGNYTE trial in anti-PD1 failed melanoma showed strong data; BLA submission expected 2H 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.